Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Dec;38(5):689-697.
doi: 10.1002/hon.2784. Epub 2020 Aug 19.

Targeted next-generation sequencing reveals molecular heterogeneity in non-chronic lymphocytic leukemia clonal B-cell lymphocytosis

Irene Defrancesco  1 , Silvia Zibellini  2 , Emanuela Boveri  3 , Marco Frigeni  2   4 , Virginia Valeria Ferretti  1 , Ettore Rizzo  5 , Arturo Bonometti  1   3 , Francesca Capuano  1   3 , Chiara Candido  2 , Sara Rattotti  2 , Annamaria Tenore  2 , Cristina Picone  2 , Elena Flospergher  1 , Caterina Zerbi  1 , Fabio Bergamini  1 , Nicole Fabbri  1 , Caterina Cristinelli  1 , Marzia Varettoni  2 , Marco Paulli  1   3 , Luca Arcaini  1   2
Affiliations

Targeted next-generation sequencing reveals molecular heterogeneity in non-chronic lymphocytic leukemia clonal B-cell lymphocytosis

Irene Defrancesco et al. Hematol Oncol. 2020 Dec.

Abstract

Non-chronic lymphocytic leukemia (non-CLL) clonal B-cell lymphocytosis (CBL) encompasses a heterogeneous group of hematologic disorders that are still poorly understood. To shed light on their biological aspects, we retrospectively analyzed a highly selected series of 28 patients, who had a clonal B-cell population in the peripheral blood and in the bone marrow, without evidence of lymphoma. Extended targeted next-generation sequencing revealed wide molecular heterogeneity with MYD88 (14%), PDE4DIP (14%), BIRC3 (11%), CCND3 (11%), NOTCH1 (11%), and TNFAIP3 (11%) as the most mutated genes. Mutations of MYD88 were "nonclassic" in most cases. Although some genetic lesions were overlapping with indolent lymphomas, mainly splenic B-cell lymphomas of marginal zone origin and splenic diffuse red pulp small B-cell lymphoma, the genetic profile of our non-CLL CBL series seemed to suggest that various pathways could be involved in the pathogenesis of these disorders, not mirroring any specific lymphoma entity. These data better enlighten the molecular characteristics of non-CLL CBL; however, more efforts are needed in order to improve the diagnostic process, prognostication, and clinical management.

Keywords: clonal B-cell lymphocytosis; marginal zone lymphoma; next-generation sequencing.

PubMed Disclaimer

References

REFERENCES
    1. Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127(20):2375-2390. https://doi.org/10.1182/blood-2016-01-643569.
    1. Xochelli A, Kalpadakis C, Gardiner A, et al. Clonal B-cell lymphocytosis exhibiting immunophenotypic features consistent with a marginal-zone origin: is this a distinct entity? Blood. 2014;123(8):1199-1206. https://doi.org/10.1182/blood-2013-07-515155.
    1. Kalpadakis C, Pangalis GA, Vassilakopoulos TP, et al. Detection of L265P MYD-88 mutation in a series of clonal B-cell lymphocytosis of marginal zone origin (CBL-MZ). Hematol Oncol. 2017;35(4):542-547. https://doi.org/10.1002/hon.2361.
    1. Bruscaggin A, Monti S, Arcaini L, et al. Molecular lesions of signalling pathway genes in clonal B-cell lymphocytosis with marginal zone features. Br J Haematol. 2014;167(5):718-720. https://doi.org/10.1111/bjh.13052.
    1. Parker H, McIver-Brown NR, Davis ZA, et al. CBL-MZ is not a single biological entity: evidence from genomic analysis and prolonged clinical follow-up. Blood Adv. 2018;2(10):1116-1119. https://doi.org/10.1182/bloodadvances.2018019760.

Substances

LinkOut - more resources